Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb

NCT04625985 is registered in ClinicalTrials.gov with Laboratorios Silanes S.A. de C.V. as lead sponsor.

NCT NCT04625985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04625985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb
Lead sponsor
Laboratorios Silanes S.A. de C.V.
Phase
Phase 2
Overall status
Completed
Start date
July 14, 2020
Completion date
March 18, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe acute respiratory syndrome coronavirus 2